Keyword: American Association For Cancer Research
After a blow in first-line lung cancer, BMS is clinging to its share of the second-line market. And it’s hoping new long-term data can help it hang on.
Lynparza earlier this year scored a phase 3 win in pancreatic cancer. Now, another PARP drug has shown some early success in the disease, too.
Last AACR, Merck’s Keytruda-chemo put up stellar lung cancer data. This year, Merck was back to show the combo held up in tough-to-treat patients.
Merck is awaiting an FDA decision for Keytruda in previously treated small cell lung cancer, and it has new numbers to boost its case.
Astellas is looking to snap up share with Xospata before an AML rival hits the scene, and new survival data could help speed that process along.
AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med.
Bristol-Myers' Opdivo-Yervoy combo has found success treating various common tumors. But the duo can help some patients with rare tumors, too.